Regulators of proteostasis are translationally repressed in fibroblasts from sporadic and LRRK2-G2019S Parkinson's patients
Dani FlinkmaniD, Ye HongiD, Jelena GnjatoviciD, Prasannakumar DeshpandeiD, Zsuzsanna OrtutayiD, Sirkku A. PeltoneniD, Valtteri KaasineniD, Peter JamesiD, Eleanor T. CoffeyiD
Abstract
Parkinsons disease (PD) is characterized by heterogeneous motor and non-motor symptoms. The majority of PD cases are sporadic, whereas the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation is the most common monogenic cause of familial PD and symptomatically indistinguishable from the sporadic form. Deficits in protein synthesis have been reported in PD. However, it is not known which proteins are affected or if there are synthesis differences between patients with sporadic and LRRK2 G2019S PD. Here we used non-canonical amino acid labeling and mass-spectrometry based proteomics to perform a quantitative comparison of nascent proteins in fibroblasts from sporadic and G2019S mutation PD patients compared to healthy individuals. We found that several proteins were under-represented among nascent proteins in cells from PD patients. Among these were regulators endo-lysosomal sorting, mRNA processing and translation itself. We further validated which of these proteins were dysregulated at the static proteome level using targeted proteomics. Key downregulated proteins included the autophagy regulator ATG9A and translational stability regulator YTHDF3. Notably, 68% of the identified proteins were downregulated in both sporadic and LRRK2-G2019S forms of PD. We identify translational repression of key regulators of proteostasis in patient fibroblasts that are common to both sporadic and LRRK2-G2019S PD.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 20
- FWCI
- 3.57
- Field percentile
- top 7%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Protein synthesis is suppressed in sporadic and familial Parkinson's Disease by LRRK2
Prasannakumar Deshpande, Dani Flinkman, … Eleanor T. Coffey·The FASEB JournalPeer-reviewed·Sep 14, 2020
- Phospho-signalling deregulation of the mTOR pathway in fibroblasts from LRRK2 Parkinson s patients
Rodolfo Alejandro, Joaquín Fernández‐Irigoyen, … Mario Ezquerra·bioRxiv·Dec 9, 2025
- Transcriptomics analyses of the LRRK2 protein interactome reveal distinct molecular signatures for sporadic and LRRK2 Parkinson's Disease
Yibo Zhao, Matthew Bracher‐Smith, … Claudia Manzoni·bioRxiv·Sep 12, 2023
- Pharmacological rescue of impaired mitophagy in Parkinson's disease-related LRRK2 G2019S knock-in mice
F. Singh, A. R. Prescott, … I. Ganley·bioRxiv·Dec 7, 2020
- LRRK2 G2019S variant is associated with transcriptional changes in Parkinson's disease human myeloid cells under proinflammatory environment
Elisa Navarro, Anastasia G. Efthymiou, … Towfique Raj·Journal of NeuroinflammationPeer-reviewed·Aug 8, 2026
- LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation
Francesca Pischedda, Maria‐Daniela Cirnaru, … Giovanni Piccoli·BrainPeer-reviewed·Feb 26, 2021